
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
January 17, 2024
CEO Joseph Johnson discusses the creation of digital tools that allow transparency within the boating market, making waves by setting standards for industry sales.